Abstract：Objective To observe the clinical effect of Entecavir combined with Silybin in the treatment of chronic hepatitis B with non-alcoholic fatty liver disease. Methods A total of 120 patients with chronic hepatitis B and non-alcoholic fatty liver disease who treated in our hospital from January 2018 to September 2019 were selected as the research subjects and divided into the control group and the experimental group by random number table method, with 60 cases in each group. The control group was treated with Entecavir, and the experimental group was treated with Entecavir combined with Silybin. The liver function indexes (alanine aminotransferase [ALT], aspartate aminotransferase[AST], hepatitis B virus DNA [HBV-DNA]), the blood lipid indexs (total cholesterol [TC], triacylglycerol [TG], high density lipoprotein cholesterol [HDL-C], low density lipoprotein cholesterol [LDL-C]), abdominal B-ultrasound grading before and after treatment, clinical efficacy and adverse reactions of the two groups were compared. Results There were no statistically significant differences in the levels of ALT, AST and HBV-DNA between the two groups before treatment (P＞0.05). After treatment, the levels of ALT, AST and HBV-DNA in the experimental group were lower than those in the control group, and the differences were statistically significant (P＜0.05). There were no statistically significant differences in the levels of TC, TG, HDL-C and LDL-C between the two groups before treatment (P＞0.05). After treatment, the levels of TC, TG and LDL-C in the experimental group were lower than those in the control group, the level of HDL-C was higher than that in the control group, and the differences were statistically significant (P＜0.05).There was no statistically significant difference between the two groups in the abdominal B-ultrasound grading before treatment (P＞0.05). After treatment, the abdominal B-ultrasound grading in the experimental group was better than that in the control group, and the difference was statistically significant (P＜0.05). The total effective rate of the experimental group was higher than that of the control group, the total incidence of adverse reactions was lower than that of the control group, and the differences were statistically significant (P＜0.05). Conclusion The effect of Entecavir combined with Silybin in the treatment of patients with chronic hepatitis B and non-alcoholic fatty liver disease is more accurate. It can significantly improve the liver function indexs and blood lipid indexs of patients, improve the total effective rate of treatment, reduce the total incidence of adverse reactions, and it is worthy of clinical promotion and application.
陈曼；张洪利. 恩替卡韦联合水飞蓟宾治疗慢性乙型肝炎并非酒精性脂肪肝的临床效果[J]. 中国当代医药, 2020, 27(29): 53-56.
CHEN Man ZHANG Hong-li. Clinical effect of Entecavir combined with Silybin in the treatment of chronic hepatitis B with non-alcoholic fatty liver disease. 中国当代医药, 2020, 27(29): 53-56.
京公网安备 11010502046607号